Unresectable Gastroesophageal Junction Adenocarcinoma Completed Phase 0 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Completed0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03395847Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal AdenocarcinomaTreatment